Caraco Recalls Cephalexin Capsules Due to Manufacturing Deviations
Caraco Pharmaceutical is recalling Cephalexin Capsules, 250 mg, because the active ingredients were not manufactured with good manufacturing practices.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which typically involves a reasonable probability of temporary or medically reversible health consequences. The source text does not report any illnesses or injuries, and the hazard is related to manufacturing deviations rather than a specific high-risk pathogen or structural defect.
Plain-English summary
Caraco Pharmaceutical Laboratories, Ltd. is recalling Cephalexin Capsules, USP, 250 mg, in 100-count and 500-count bottles. The recall is due to Current Good Manufacturing Practice (CGMP) deviations, specifically because the active pharmaceutical ingredients (APIs) were not manufactured with good manufacturing practices.
The affected products are prescription-only and were distributed nationwide and in Puerto Rico. The recall includes specific lot numbers and expiration dates ranging from September 2014 to September 2015. The products were manufactured by Sun Pharmaceutical Ind. Ltd. in India.
Consumers and healthcare providers should stop using the affected lots and return them to the pharmacy or point of purchase. No specific adverse health consequences or illnesses have been reported in the source text.
The recalled product
- Product
- Cephalexin Capsules, USP, 250 mg, packaged in a) 100-count bottles (NDC 62756-293-88) and b) 500-count bottles (NDC 62756-293-13), Rx only, Manufactured by: Sun Pharmaceutical Ind. Ltd., Acme Plaza, Andheri-Kurla Road, Andheri (East), Mumbai-400 059, India.
- Manufacturer
- Caraco Pharmaceutical Laboratories, Ltd.
- Category
- Drug — Antibiotic
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot #: a) AGL0098B
- AGL0099B
- AGL0100B
- AGL0101B
- Exp 09/14
- AGM0073B
- AGM0074B
- Exp 04/15
- AGM0125B
- AGM0126B
- Exp 07/15
- AGM0158B
- Exp 09/15
- b) AGL0092A
- AGL0093A
- AGL0094A
- AGL0095A
- AGL0096A
- AGL0097A
- AGL0102A
Distribution
Part of a larger recall action
This product is one of 2 recalled by Caraco Pharmaceutical Laboratories, Ltd. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · Caraco Pharmaceutical Laboratories, Ltd.
See all →- ModerateCaraco Recalls Cephalexin Capsules Due to Manufacturing Practice Deviations
FDA (Drugs) · 2014-08-13
- ModerateCaraco Recalls Venlafaxine Hydrochloride Extended-Release Tablets for Dissolution Failures
FDA (Drugs) · 2014-07-09
- SevereCaraco Recalls Gemcitabine Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2014-07-02
- ModerateCaraco Recalls Venlafaxine Hydrochloride Extended-Release Tablets for Dissolution Failures
FDA (Drugs) · 2014-05-07
- ModerateCaraco Recalls Children's Cetirizine Tablets Due to Impurity Failures
FDA (Drugs) · 2014-05-07
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- ModerateSildenafil Citrate Recall Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19